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A common polymorphism in NR1H2 (LXRbeta) is
associated with preeclampsia
Kevin Mouzat1*, Eric Mercier2, Anne Polge1, Alexandre Evrard1, Silvère Baron3, Jean-Pierre Balducchi4,
Jean-Paul Brouillet1, Serge Lumbroso1† and Jean-Christophe Gris2†
Abstract
Background: Preeclampsia is a frequent complication of pregnancy and a leading cause of perinatal mortality.
Both genetic and environmental risk factors have been identified. Lipid metabolism, particularly cholesterol
metabolism, is associated with this disease. Liver X receptors alpha (NR1H3, also known as LXRalpha) and beta
(NR1H2, also known as LXRbeta) play a key role in lipid metabolism. They belong to the nuclear receptor
superfamily and are activated by cholesterol derivatives. They have been implicated in preeclampsia because they
modulate trophoblast invasion and regulate the expression of the endoglin (CD105) gene, a marker of
preeclampsia. The aim of this study was to investigate associations between the NR1H3 and NR1H2 genes and
preeclampsia.
Methods: We assessed associations between single nucleotide polymorphisms of NR1H3 (rs2279238 and
rs7120118) and NR1H2 (rs35463555 and rs2695121) and the disease in 155 individuals with preeclampsia and 305
controls. Genotypes were determined by high-resolution melting analysis. We then used a logistic regression
model to analyze the different alleles and genotypes for those polymorphisms as a function of case/control status.
Results: We found no association between NR1H3 SNPs and the disease, but the NR1H2 polymorphism rs2695121
was found to be strongly associated with preeclampsia (genotype C/C: adjusted odds ratio, 2.05; 95% CI, 1.04-4.05;
p = 0.039 and genotype T/C: adjusted odds ratio, 1.85; 95% CI, 1.01-3.42; p = 0.049).
Conclusions: This study provides the first evidence of an association between the NR1H2 gene and preeclampsia,
adding to our understanding of the links between cholesterol metabolism and this disease.
Background
Preeclampsia (PE) is a frequent complication of the sec-
ond half of pregnancy and is one of the leading causes of
maternal perinatal mortality and morbidity [1]. This con-
dition, affecting 2.5 to 3% of pregnant women is defined
by gestational hypertension accompanied by proteinuria
[2,3]. Many risk factors have been described, including,
in particular, cardiovascular risks, such as diabetes melli-
tus and high body mass index [4,5]. Cholesterol metabo-
lism may also contribute to the pathogenesis of
preeclampsia. Indeed, high total cholesterol and LDL
(low density lipoprotein)-cholesterol levels are signifi-
cantly associated with this disease [6]. Moreover, it has
been shown that a familial history of PE almost triples
the risk of a woman developing this disease, consistent
with the involvement of genetic factors [4]. Many risk
factors have been described, but the molecular mechan-
isms underlying this disease remain unclear. Liver X
receptors (LXRs) NR1H3 and NR1H2, more commonly
known as LXRalpha and LXRbeta, play a key role in cho-
lesterol metabolism [7,8]. They belong to a subclass of
nuclear receptors that form obligate heterodimers with
9-cis retinoic acid receptors (RXR). They also bind to and
are activated by naturally occurring oxidized forms of
cholesterol, known as oxysterols, the intracellular con-
centrations of which are directly correlated with choles-
terol concentration [9]. Knockout mice deficient in
oxysterol synthesis pathways are unable to induce LXR-
target genes in response to dietary cholesterol, demon-
strating that these nuclear receptors are endogenous
receptors for oxysterols [10]. Upon ligand binding, they
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activate the transcription of many genes involved essen-
tially in lipid metabolism, cholesterol metabolism in
particular. Thus, by stimulating the cellular efflux and
hepatic reverse transport of cholesterol and inhibiting its
endogenous synthesis, they act as hypocholesterolemic
factors [11]. LXRs may therefore be considered endogen-
ous cholesterol sensors.
LXRs are promising candidates in investigations of the
molecular causes of PE. It is now widely accepted that PE
results from placentation defects. Indeed, any defect in
trophoblast development or differentiation can result in
PE [12]. LXRs are expressed in human placenta at various
stages of pregnancy, right until term [13], and their
expression increases during pregnancy [14]. In addition to
their potential role in regulating placental lipid metabo-
lism, LXRbeta has recently been shown to control tropho-
blast invasion in vitro [15]. Furthermore, we have also
shown that ENG, encoding endoglin (CD105), a protein
controlling placental angiogenesis [16], is a direct target of
LXRalpha [17]. Soluble ENG is a marker of PE, and its
serum concentration is tightly correlated with disease
severity.
Single nucleotide polymorphisms (SNP) of the NR1H3
(LXRalpha) and NR1H2 (LXRbeta) genes have recently
been associated with many metabolic indicators and con-
ditions, including circulating total, LDL and HDL (High
Density Lipoprotein)-cholesterol levels for NR1H3 [18-20],
and type 2 diabetes mellitus and obesity for both NR1H3
and NR1H2 [21-24]. Based on these previous studies, we
selected two SNPs (rs2279238 and rs7120118) in the
NR1H3 gene, mapping to chromosome 11p11.2 and two
SNPs (rs2695121 and rs35463555) in the NR1H2 gene,
mapping to chromosome 19q13.3 for study. Rs2279238,
rs2695121 and rs35463555 have been reported to be asso-
ciated with obesity [22]; rs2279238 is also associated with
risk factors for type 2 diabetes mellitus [23]. Finally,
rs7120118 was chosen for study because it has been
shown to be associated with HDL-cholesterol levels [20].
In a case-control study of 155 preeclamptic and 305 nor-
mal pregnancies based on a powerful high-resolution
melting curve analysis technique, we showed that the
NR1H2 polymorphism rs2695121 was strongly associated
with PE. These findings suggest that further studies of the
role of LXRbeta in the pathogenesis of this disease will be
of interest. By contrast, we found no significant association
between the NR1H3 SNPs (rs2279238 and rs7120118) and
PE.
Methods
Ethics statement
This study was approved by the local ethics committee
(CPP: Comité de Protection des Personnes Sud Méditerra-
née III). We recruited 155 patients between December
1997 and July 2002. Both cases and controls gave written
informed consent for participation in the study. The clin-
ical investigation was performed in accordance with the
Helsinki Declaration and its amendments.
Patients and controls
All the patients and controls were primiparous.
Patients were referred to the outpatient clinic of the
Gynecology and Obstetrics Department or to the Hema-
tology Laboratory, University Hospital of Nîmes, between
December 1997 and July 2002, for thrombophilia screen-
ing and relevant investigations.
The inclusion criterion for the patients was preeclampsia
during a natural pregnancy, defined as gravidic hyperten-
sion (systolic blood pressure [BP] > 140 mm Hg, diastolic
BP > 90 mm Hg, a rise in systolic BP > 30 mm, or a rise in
diastolic BP > 15 mm Hg on at least two measurements
6 hours apart) after 20 weeks, associated with significant
proteinuria (> 300 mg/24 h). Thirty-six of the 155 pree-
clampsia patients had developed a severe form according
to current definitions, before 34 weeks of gestation in nine
cases. There were 11 cases of HELLP (hemolysis, elevated
liver enzymes, low platelets) syndrome and two cases of
eclampsia. We were unable to analyze severity subgroups,
due to the small number and heterogeneity of the severe
preeclampsia cases.
The 305 controls were women from the NOHA First
Cohort, with uneventful pregnancies [25].
Data were collected for putative clinical predictors of
preeclampsia: age, body mass index (BMI), smoking
(defined as at least one cigarette per day), gravidity (evalu-
ating the number of previous miscarriages), ethnicity, dia-
betes mellitus, pre-existing arterial hypertension (defined
as the use of hypertensive medication, a systolic blood
pressure of at least 140 mm Hg or a diastolic blood pres-
sure of at least 90 mm Hg on two readings taken in a
supine position 5 min apart, and on two separate occa-
sions) and maternal history of preeclampsia.
SNP genotyping
Genomic DNA was extracted from 10 ml of peripheral
maternal whole blood collected into tubes containing
EDTA (ethylenediaminetetraacetic acid) and sodium
chloride, as described elsewhere [26]. The SNPs chosen
for study were genotyped, as previously described [27].
Briefly, 10 ng of genomic DNA was subjected to PCR
(polymerase chain reaction) amplification with LightCy-
cler® 480 High-Resolution Melting Master Mix (Roche
Diagnostics, Meylan, France), using a touchdown protocol
as follows: initial denaturation at 95°C for 10 minutes then
50 cycles of denaturation at 95°C for 10 seconds; annealing
at temperatures decreasing from 70°C to 60°C (step size:
0.5°C/cycle) for 20 seconds and elongation at 72°C for
20 seconds. High-resolution melting curve data were
obtained by monitoring the decrease in fluorescence from
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75°C to 95°C at a rate of 25 acquisitions per degree Celsius
on a LightCycler® 480 apparatus (Roche Diagnostics). The
sequences of the primers used for PCR are given in table
1. Fluorescence data were visualized by normalization,
temperature-shifting and difference plotting, and were
then analyzed with LightCycler® Gene Scanning software
(Roche Diagnostics). Melting curve analysis for rs2279238
and rs7120118 generated three distinct profiles corre-
sponding to the three possible genotypes (frequent homo-
zygous, heterozygous and rare homozygous, according to
the NCBI SNP database (dbSNP; human build 132)). The
identification of rare homozygous genotypes for rs2695121
and rs35463555 was made possible by diluting each sam-
ple with a known frequent homozygous genotype (2 ng)
before PCR, thus generating a heterozygous profile,
according to the kit manufacturer’s recommendations.
Genotyping results were confirmed by directly sequencing
the PCR products of 10% of the samples with the primers
used for PCR. PCR products were purified with the Agen-
court AMPure XP kit (Beckman Coulter Genomics,
Grenoble, France), according to the manufacturer’s recom-
mendations. Sequencing reactions were carried out with
the BigDye® Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems, Courtaboeuf, France) and products
were purified with the CleanSEQ kit (Beckman Coulter
Genomics), according to the manufacturer’s instructions.
The purified products were then resolved on a 3130xl
Genetic Analyzer (Applied Biosystems).
Statistical analysis
Deviation from Hardy-Weinberg equilibrium (HWE) was
assessed with DeFinetti software (T.F. Wienker and T.M.
Strom, unpublished data, http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl). The frequencies of particular alleles and geno-
types in cases and controls were assessed by c2 analysis
(Statview software 5.0, SAS Institute). Analyses of the pair-
wise linkage disequilibrium (D’ and r2) between the mar-
kers in each genomic region and haplotype analysis were
carried out with Haploview 4.2 Software [28].
The putative predictors of preeclampsia – the clinical
factors listed above and the four polymorphisms studied –
were evaluated in women, initially by univariate analysis
and then by multivariate logistic regression analysis. We
calculated the corresponding crude odds ratio (cOR) and
its 95% confidence interval (95% CI) and then the adjusted
odds ratio (aOR) and its 95% CI. Variables for multivariate
models were selected in a stepwise manner, beginning
with all the variables for which p < 0.25 in univariate mod-
els as potential predictors, with final adjustment for all
variables for which p < 0.25 in the univariate models.
Results
Characteristics of the participants
The characteristics of controls and patients at diagnosis
are presented in table 2. There were no significant differ-
ences in age, ethnicity or percentage of smokers between
the two groups. Body mass index, and the percentages of
women with two previous spontaneous miscarriages, dia-
betes mellitus, pre-existing arterial hypertension or a
maternal history of PE were significantly higher in the PE
group than in controls.
Polymorphisms and risk of preeclampsia
Tables 3 and 4 show the allelic and genotypic frequencies,
respectively, for cases and controls. Genotyping of the
SNPs in the NR1H3 (LXRalpha) gene revealed that the T
allele of rs2279238 was found in 14.10% of controls and
11.69% of cases; the C allele of rs7120118 was found in
25.74% of controls and 23.87% of cases. For the NR1H2
(LXRbeta) gene, the A allele of rs35463555 was found in
27.38% of controls and 32.90% of cases. The allelic fre-
quencies of these three SNPs did not significantly differ
between cases and controls. By contrast, the C allele of
rs2695121 was found in 54.43% of controls and 64.84% of
cases (p = 0.003). None of the distributions for the alleles
and genotypes of the SNPs analyzed deviated from Hardy-
Weinberg equilibrium in either cases or controls (data not
shown).
We used these data to generate logistic regression mod-
els for each of the SNPs genotyped (Table 5). Univariate
analyses indicated that the genotype distributions of
NR1H3 (LXRalpha) SNPs (rs2279238 and rs7120118) did
not differ significantly between cases and controls. The
risk of PE in carriers of homozygous and heterozygous
Table 1 Sequence primers used for high-resolution melting curve analyses
SNP (gene) 5’-3’ sequences Size of the amplicon (bp)
rs2279238 (NR1H3) Fw: GAGAGCGTTGAAGCACTTTC 140
Rev: GCTCAGAACATTGTAGTGGAAG
rs7120118 (NR1H3) Fw: CCTTTGGCACTTGTAGACTCAT 159
Rev: GGAGGGGAGGAGACTTGAC
rs35463555 (NR1H2) Fw: CAGGAAGGAAGTGACAGAGACA 111
Rev: CCATCGTTTGAGATTGTGGA
rs2695121 (NR1H2) Fw: GGCAGGTCTTGTTAGAAGGA 171
Rev: AATACAGGGGATTGAGAGCC
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variant alleles for these two SNPs was similar to that in
individuals homozygous for the wild-type alleles. Interest-
ingly, both NR1H2 (LXRbeta) SNPs (rs35463555 and
rs2695121) were found to be significantly associated with
preeclampsia, which was more frequent in individuals
homozygous for the mutated alleles. After adjustment for
putative clinical predictors of preeclampsia – pre-existing
arterial hypertension, BMI, maternal history of PE, gravid-
ity, diabetes mellitus, age and smoking – NR1H2 SNP
rs2695121 continued to be an independent risk factor for
preeclampsia in multivariate logistic regression analysis
(table 6). This significance was retained for the homozy-
gous mutated allele C, unmasked for the heterozygous
allele C and lost for the NR1H2 SNP rs35463555.
Haplotype analysis
By studying the combinations of the two polymorphisms in
each gene, we identified three common haplotypes for the
NR1H3 (LXRalpha) gene and four for the NR1H2
(LXRbeta) gene (table 7). None of NR1H3 haplotypes was
associated with PE. The two haplotypes of the NR1H2 gene
(GT and AC) were associated with preeclampsia (p = 0.009
and p = 0.026, respectively). Haploblock analysis revealed
that the two markers within each of the genes studied were
in linkage disequilibrium (Additional file 1, Figure S1).
Discussion
This is the first study to investigate the association of
the NR1H2 (LXRbeta) gene with preeclampsia. We
report here a new genetic association between the SNP
rs2695121, in the NR1H2 gene, and preeclampsia. By
contrast, the two SNPs within the NR1H3 (LXRalpha)
gene studied, rs2279238 and rs7120118, were not identi-
fied as independent risk factors for this disease.
The four SNPs studied here were chosen on the basis
of previously identified genetic associations with other
Table 2 Clinical characteristics of controls and patients
Characteristics Controls (N = 305) Patients (N = 155) p-valuea cOR (95% CI) p-valueb
Age 29 ± 7 (23-36) 30 ± 7 (23-37) 0.103 1.04 (0.99-1.09) 0.099
BMI 22.46 ± 2.60
(16.32-28.50)
22.80 ± 2.45
(17.74-29.40)
0.063 1.12 (1.02-1.22) 0.021
Smoking 13 (4.26) 3 (1.94) 0.309 0.44 (0.12-1.58) 0.210
Gravidity: 0.076
1 259 (84.92) 121 (78.06) 1
2 35 (11.48) 21 (13.55) 1.28 (0.72-2.30) 0.400
3 11 (3.61) 13 (8.39) 2.53 (1.10-5.81) 0.029
Ethnicity: 0.690
Caucasian 291 (95.41) 145 (93.55) 1
African 8 (2.62) 6 (3.87) 1.51 (0.51-4.42) 0.457
Asian 6 (1.97) 4 (2.58) 1.34 (0.37-4.82) 0.656
Diabetes Mellitus 4 (1.31) 7 (4.52) 0.071 3.56 (1.03-12.4) 0.046
Pre-existing arterial hypertension 8 (2.62) 12 (7.74) 0.021 3.12 (1.25-7.79) 0.015
Maternal PE antecedent 10 (3.28) 13 (8.39) 0.032 2.70 (1.16-6.31) 0.022
Age and BMI are presented as medians ± interquartile range and ranges are indicated in brackets. For nominal values, percentages are indicated in brackets. a:
Mann-Whitney test for continuous variables; b: chi-square test for nominal variables. Abbreviations: BMI, body mass index; cOR, crude odds ratio; 95% CI, 95%
confidence interval.
Table 3 Allelic counts and frequencies of studied polymorphisms
SNP (gene) SNP Allele Controls Cases p-value
LXRalpha (NR1H3) rs2279238 C 524 (85.90) 272 (88.31)
T 86 (14.10) 36 (11.69) 0.310
rs7120118 T 453 (74.26) 236 (76.13)
C 157 (25.74) 74 (23.87) 0.648
LXRbeta (NR1H2) rs35463555 G 443 (72.62) 208 (67.10)
A 167 (27.38) 102 (32.90) 0.082
rs2695121 T 278 (45.57) 109 (35.16)
C 332 (54.43) 201 (64.84) 0.003
The table presents total counts for each allele. The percentages of the alleles in each group (controls or cases) are indicated in brackets. A difference in allele
distribution between the two groups was considered significant if the p-value was less than 0.05.
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physiological or physiopathological conditions. The
rs2279238 SNP (NM_005693.2:c.297C > T (p. =)) is
located within exon 4 of the NR1H3 gene (Figure 1A),
but the nucleotide variation is synonymous, resulting in a
protein sequence identical to that of the wild type. We
also used four splice site prediction programs (SpliceSite-
Finder-like, MaxEntScan, NNSPLICE and Human Splicing
Finder) in Alamut 2.0 Software (Interactive Biosoftware,
Mont-Saint-Aignan, France). These programs were unable
to detect any clear splicing site modifications induced by
the SNP within the gene. The SNP did not result in a pre-
dicted miRNA (microRNA) binding site (identified by
MicroCosm Targets software) either. It is thus highly unli-
kely that this SNP was functional at the molecular level.
Similarly, rs7120118 (NM_005693.2:c.988+2721T > C),
which is located within an intron, would be unlikely to
affect protein sequence and/or activity. The NR1H2 SNP
rs2695121 (NM_007121.4:c.-19-103T > C), which was
found to be associated with preeclampsia, is an intronic
polymorphism that would therefore also be unlikely to
affect protein function. This hypothesis was confirmed
with the splice site prediction module of Alamut software.
However, rs35463555 (NT_011109.16:g.23145898G > A),
which was also found to be associated with PE in a uni-
variate logistic regression model, is located within the pro-
moter of the gene, 2 kb upstream from the transcription
start site (Figure 1B). MatInspector analysis (Genomatic
Software Suite, München, Germany) showed that this SNP
was part of the core sequence of the NR2F (COUP-TFs)
orphan nuclear receptor responsive element (data not
shown). This program failed to identify this putative
sequence when the A allele of the SNP was considered.
An siRNA (small interfering RNA) directed against NR2F1
(COUP-TF1) has been shown to downregulate LXR
expression and the expression of many LXR target genes
in muscle cell cultures [29]. However, the authors of this
previous study did not investigate the molecular mechan-
ism underlying this regulation; no direct regulation of
NR1H2 by COUP-TFs has thus been demonstrated to
date. Moreover, the potential role of COUP-TFs in
Table 5 Logistic regression analysis of the associations
between LXRalpha or LXRbeta SNPs and preeclampsia
(univariate analysis)
Gene SNP Genotype cOR 95% CI p-value
LXRalpha (NR1H3) rs2279238 C/T 0.87 0.55-1.38 0.551
T/T 0.32 0.04-2.65 0.288
rs7120118 T/C 0.94 0.63-1.40 0.742
C/C 0.71 0.27-1.87 0.485
LXRbeta (NR1H2) rs35463555 G/A 0.99 0.65-1.49 0.949
A/A 2.35 1.19-4.63 0.014
rs2695121 T/C 1.62 0.92-2.86 0.097
C/C 2.30 1.29-4.11 0.005
Abbreviations: cOR, crude odds ratio; 95% CI, 95% confidence interval.
Table 4 Genotypic counts and frequencies of the studied
polymorphisms
Gene SNP Genotype Controls Cases
LXRalpha (NR1H3) C/C 225 (73.77) 119 (77.27)
rs2279238 C/T 74 (24.26) 34 (22.08)
T/T 6 (1.97) 1 (0.65)
T/T 164 (53.77) 87 (56.13)
rs7120118 T/C 125 (40.98) 62 (40.00)
C/C 16 (5.25) 6 (3.87)
LXRbeta (NR1H2) G/G 157 (51.48) 74 (47.74)
rs35463555 G/A 129 (42.30) 60 (38.71)
A/A 19 (6.23) 21 (13.55)
T/T 70 (22.95) 21 (13.55)
rs2695121 T/C 138 (45.25) 67 (43.23)
C/C 97 (31.80) 67 (43.23)
The table presents total counts for each genotype. The percentages of the
genotypes in each group (control or cases) are indicated in brackets.
Table 6 Logistic regression model of risk factors for PE
(multivariate analysis)
Factor aOR 95% CI p-value
rs2695121-T/C 1.85 1.01-3.42 0.049
rs2695121-C/C 2.05 1.04-4.05 0.039
rs35463555-G/A 0.78 0.49-1.24 0.295
rs35463555-A/A 1.32 0.59-2.97 0.500
Pre-existing arterial hypertension 3.74 1.44-9.73 0.007
BMI 1.09 0.99-1.21 0.086
Maternal history of PE 2.35 0.95-5.80 0.065
Gravidity: 2 1.25 0.68-2.30 0.478
Gravidity: 3 2.89 1.22-6.88 0.016
Diabetes mellitus 3.35 0.90-12.5 0.073
Age 1.05 0.99-1.10 0.070
Smoking 0.66 0.18-2.46 0.535
Abbreviations: aOR, adjusted odds ratio; 95% CI, 95% confidence interval.
Table 7 Haplotypic prevalence of genotyped NR1H3 and
NR1H2 in both groups
Gene Haplotype Controls (%) Cases (%) p-value
LXRalpha (NR1H3) CT 0.742 0.755 0.687
TC 0.141 0.109 0.183
CC 0.117 0.129 0.579
LXRbeta (NR1H2) GT 0.433 0.343 0.009
GC 0.293 0.328 0.280
AC 0.251 0.320 0.026
AT 0.023 0.009 0.126
Haplotype frequencies were compared between cases and controls, in chi-
squared tests.
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preeclampsia has never been investigated. Based on the
results of this bioinformatic simulation, it may be interest-
ing to evaluate the molecular effect of rs35463555 on the
transcription of the gene encoding LXRbeta. These predic-
tions suggest that the positive association between the
NR1H2 rs2695121 SNP and preeclampsia may result from
an indirect association rather than a direct effect of the
polymorphism on protein function [30]. Thus, rs2695121
may be in linkage disequilibrium with an unobserved cau-
sal locus, which might even be located within another
gene in the vicinity of NR1H2.
Despite the demonstration of an interesting association
between the r2695121 polymorphism in NR1H2 (LXRbeta)
and preeclampsia, this study was subject to several limita-
tions. Univariate logistic regression analysis showed that
both the SNPs within the NR1H2 gene tested were asso-
ciated with preeclampsia. However, in a multivariate
model including all the clinical cofactors and these two
polymorphisms, only rs2695121 remained associated with
PE. This association was strengthened by a significant
adjusted link between the mutated homozygous but also
heterozygous SNP and preeclampsia, but the lack of asso-
ciation between rs35463555 and the diseases warrants
further investigation. It may result from there being too
few samples in our study, but it could also reflect genetic
linkage between the two polymorphisms. We calculated
the linkage disequilibrium between the two polymorph-
isms in our genotyped population and we found evidence
of genetic linkage between the two polymorphisms (D’ =
0.85; r2 = 0.21; Additional file 1, Figure S1), likely to
account, at least in part, for the apparent lack of statistical
power in our study.
Many risk factors for preeclampsia have been
described. High body mass index, obesity and cholestero-
lemia are among the most frequently studied and are
tightly linked to this disease [6,31]. High total and LDL-
cholesterol levels have been identified as risk factors for
preeclampsia. Our discovery of an association between a
polymorphism of NR1H2 (LXRbeta) and PE is therefore
of particular interest. Indeed, both LXRs are now widely
considered to be major regulators of lipid homeostasis. In
recent years, many studies in animals and in vitro models
have demonstrated that these nuclear receptors modulate
the expression of genes involved in various aspects of the
control of cholesterol metabolism (For a review, see [7]).
They may act on various pathways: inhibiting de novo
cholesterol synthesis by downregulating key enzymes
involved in its synthesis, stimulating the cellular efflux of
cholesterol by upregulating ATP-binding cassette A1, G1
and G5/G8 (ABCA1, ABCG1 and ABCG5/G8) transpor-
ters and inducing the reverse transport of cholesterol by
regulating apolipoprotein-encoding genes, such as APOE
B 
1 kb 
STOP ATG 
rs2695121 
1 2 3 4 5 6 7 8 9 10 
rs35463555 
A 
1 kb rs2279238 rs7120118 
ATG STOP 
1A 1B 2 3 4 5 6 7 8 9 10 1C 
Figure 1 Schematic representation of the NR1H3 (LXRalpha) and NR1H2 (LXRbeta) genes showing the position of the genotyped SNPs.
Rectangles indicate exons; lines indicate introns. Arrows under the schematic representation of the gene indicate the position of each
genotyped SNP. Thick lines below the gene represent the 1 kb scale. A: schematic representation of the NR1H3 (LXRalpha) gene; B: schematic
representation of the NR1H2 (LXRbeta) gene.
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(apolipoprotein E). Circulating cholesterol has been
widely described as a risk factor for preeclampsia, and
some APOE alleles have been associated with PE [32].
Our work is thus consistent with recent findings of asso-
ciations between polymorphisms in the genes encoding
LXRalpha and LXRbeta and circulating total, LDL- and
HDL-cholesterol concentrations [18-20] and obesity
[22,24].
The physiopathological features of preeclampsia seem
to result principally from placental ischemia and/or a
maternal inflammatory response [1]. Many factors are
involved in the development of this disease. In particular,
the gene encoding cyclooxygenase-2 (COX-2) has been
shown to be overexpressed in the vessels of women with
PE [33], and circulating levels of proinflammatory cyto-
kines, such as inteleukin-6 (IL-6), are higher in patients
than in controls [34]. In addition to their well known
cholesterolemia-lowering effects, LXRs have been impli-
cated in immune processes. Their anti-inflammatory
action was first described in 2003 in a study showing that
their activation decreased the expression of many proin-
flammatory factors, including COX-2, iNOS (inducible
nitric oxide synthase), IL-1beta (interleukin-1 beta) and
IL-6 [35]. Thus, further studies on the role of LXRs in
the immune processes associated with preeclampsia will
be of particular interest.
Placental angiogenesis also makes a major contribution
to preeclampsia. Indeed, defects in the development, dif-
ferentiation and angiogenesis of the placenta may lead to
PE [12]. Defects in signaling by angiogenic factors, such
as vascular endothelial growth factor (VEGF), are also
frequently observed. Circulating levels of sFLT-1 (soluble
VEGF receptor 1) and sENG (soluble endoglin) are high
in patients suffering from PE, and may contribute to the
pathogenesis of the disease [16,32]. Interestingly, VEGF is
a direct target gene of both LXRs [36]. We have also pre-
viously reported that ENG is a direct target of LXRalpha
in human placental cell cultures [17]. Direct effects of
liver X receptors on the placenta, such as trophoblast
invasion [15,37] and syncytialization [38], have recently
been suggested. One recent study revealed that the
expression of NR1H3, NR1H2 and their target gene
ABCA1 in JAR cells is stimulated under conditions of
low oxygen concentration, mimicking the conditions
occurring in preeclampsia [14]. The authors hypothesized
that these deregulations might affect cholesterol trans-
port between the mother and the fetus. Overall, these
data provide evidence for a functional role for LXRs in
the maintenance of placental homeostasis.
Human genetic studies have recently demonstrated
associations between polymorphisms of the NR1H3
(LXRalpha) gene and circulating total, LDL- and HDL-
cholesterol [18-20]. A role for LXRalpha in the pathogen-
esis of preeclampsia is also supported by our previous
work showing that LXRalpha but not LXRbeta induced
the promoter of ENG gene [17]. Our work reveals that
the NR1H2 (LXRbeta) SNP rs2695121 is a risk factor for
preeclampsia. The lack of association between the two
tested NR1H3 SNPs and preeclampsia in our work is
quite surprising. However, we limited our study to only
two polymorphisms of NR1H3 gene, which had already
been reported to be associated with physiological and/or
pathological conditions. We cannot, on the basis of our
results, exclude the possibility that NR1H3 is involved in
the pathogenesis of preeclampsia, for two major reasons:
the statistical power of this study may simply have been
too low to pick up a significant association. Moreover,
other SNPs, located within the same gene and not in
strong linkage disequilibrium with rs2279238 and
rs7120118, may be associated with the disease. Indeed,
using Tagger implemented in Haploview software with
an aggressive tagging method (r2 threshold = 0.8) [39],
we showed that our two SNPs covered 91% of the haplo-
typic variability of the NR1H3 gene (including 2 kb on
either side of the gene; mean max r2 = 0.97). However, as
they did not account for all the variability, it is possible
that the absence of association was due to missed haplo-
types. Additional studies including more NR1H3 SNPs
and/or more samples are therefore required to rule out
definitively the existence of an association between this
gene and the disease. The two polymorphisms of the
NR1H2 gene studied (rs2695121 and rs35463555) have
not yet been genotyped in the CEU+TSI populations of
the Hapmap project. However, only three SNPs within
this gene region have been described in the Hapmap pro-
ject. These three SNPs are in strong linkage disequili-
brium, defining a unique haploblock. As the two
TagSNPs proposed by Tagger have never been associated
with any physiological or physiopathological condition,
we preferred to investigate two potentially functional
SNPs described in previous studies, despite the possible
lack of haplotypic variability coverage. A deeper replica-
tion study, including a larger number of polymorphisms,
may facilitate definition of the contribution of NR1H2 to
the pathogenesis of preeclampsia. In parallel, it will be
interesting to determine the concentration of circulating
endoglin in our cohort of patients, to identify possible
associations with NR1H2 genotypes.
Conclusions
In conclusion, we demonstrate here, for the first time, an
association between a polymorphism of the NR1H2
(LXRbeta) gene and preeclampsia. However, caution is
required in the clinical interpretation of risk factors [40].
The results of this retrospective pilot study will therefore
require confirmation in a secondary prospective study on
a set of patients, in which it should be possible to assess
the association between the SNPs and disease severity. In
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addition to improving our understanding of the molecu-
lar physiopathological features of preeclampsia, this study
opens up new possibilities for investigation. In particular,
it will be particularly interesting to determine whether
LXRbeta could serve as a new marker of the disease.
Moreover, as this nuclear receptor is an inducible tran-
scription factor, an understanding of its role in pree-
clampsia could guide the development of new ligands for
the treatment of this disease.
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respectively.
List of abbreviations used
95% CI: 95% confidence interval; ABC: ATP-binding cassette; APO:
apolipoprotein; BP: blood pressure; COUP-TF: chicken ovalbumin upstream
promoter transcription factor; COX-2: cyclooxygenase-2; HDL: high-density
lipoprotein; HELLP: hemolysis: elevated liver enzymes: low platelets; HWE:
Hardy-Weinberg equilibrium; IL-6: interleukin-6; iNOS: inducible nitric oxide
synthase; LDL: low-density lipoprotein; LXR: liver X receptor; ND: not
determinable; OR: odds ratio; PE: preeclampsia; RXR: retinoid × receptor;
sENG: soluble endoglin; sFLT-1: soluble VEGF receptor 1; SNP: single
nucleotide polymorphism; VEGF: vascular endothelial growth factor.
Acknowledgements
We thank all the participants, patients and controls who agreed to
participate in this study. We thank R. Guirard and E. Douard for excellent
technical assistance, Prof. J-M.A. Lobaccaro and Dr. Françoise Caira (UMR
CNRS 6247 - Clermont University - INSERM U931) for critically reading the
manuscript and for helpful discussions.
Author details
1Department of Biochemistry, Nimes University Hospital, F-30029 Nîmes
Cedex 9, France. 2Department of Hematology, Nimes University Hospital, F-
30029 Nîmes Cedex 9, France. 3GReD Laboratory, UMR CNRS 6247 -
Clermont University - INSERM U931, F-63177 Aubière Cedex, France.
4Department of Internal Medicine, Nimes University Hospital, F-30029 Nîmes
Cedex 9, France.
Authors’ contributions
KM, EM, SL, JCG conceived and designed the experiments. KM, EM, JCG
acquired the data. KM, JCG analyzed and interpreted the data. EM, AP, AE,
SB, JPB4, JPB1 contributed to experimental design and revised the
manuscript critically. KM, SL, JCG wrote the paper. All authors read and
approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 May 2011 Accepted: 26 October 2011
Published: 26 October 2011
References
1. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005, 365:785-799.
2. Redman CW, Sargent IL: Latest advances in understanding preeclampsia.
Science 2005, 308:1592-1594.
3. Zhang J, Zeisler J, Hatch MC, Berkowitz G: Epidemiology of pregnancy-
induced hypertension. Epidemiol Rev 1997, 19:218-232.
4. Duckitt K, Harrington D: Risk factors for pre-eclampsia at antenatal
booking: systematic review of controlled studies. Bmj 2005, 330:565.
5. Walsh SW: Obesity: a risk factor for preeclampsia. Trends Endocrinol Metab
2007, 18:365-370.
6. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G,
Romundstad PR: Prepregnancy cardiovascular risk factors as predictors of
pre-eclampsia: population based cohort study. Bmj 2007, 335:978.
7. Viennois E, Pommier AJ, Mouzat K, Oumeddour A, Hajjaji FZ, Dufour J,
Caira F, Volle DH, Baron S, Lobaccaro JM: Targeting liver X receptors in
human health: deadlock or promising trail? Expert Opin Ther Targets 2011,
15:219-232.
8. Volle DH, Lobaccaro JM: Role of the nuclear receptors for oxysterols LXRs
in steroidogenic tissues: beyond the “foie gras”, the steroids and sex?
Mol Cell Endocrinol 2007, 265-266:183-189.
9. Wong J, Quinn CM, Brown AJ: Synthesis of the oxysterol, 24(S), 25-
epoxycholesterol, parallels cholesterol production and may protect
against cellular accumulation of newly-synthesized cholesterol. Lipids
Health Dis 2007, 6:10.
10. Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW: Enzymatic
reduction of oxysterols impairs LXR signaling in cultured cells and the
livers of mice. Cell Metab 2007, 5:73-79.
11. Tontonoz P, Mangelsdorf DJ: Liver X receptor signaling pathways in
cardiovascular disease. Mol Endocrinol 2003, 17:985-993.
12. Huppertz B: Placental origins of preeclampsia: challenging the current
hypothesis. Hypertension 2008, 51:970-975.
13. Marceau G, Volle DH, Gallot D, Mangelsdorf DJ, Sapin V, Lobaccaro JM:
Placental expression of the nuclear receptors for oxysterols LXRalpha
and LXRbeta during mouse and human development. Anat Rec A Discov
Mol Cell Evol Biol 2005, 283:175-181.
14. Plosch T, Gellhaus A, van Straten EM, Wolf N, Huijkman NC, Schmidt M,
Dunk CE, Kuipers F, Winterhager E: The liver X receptor (LXR) and its
target gene ABCA1 are regulated upon low oxygen in human
trophoblast cells: a reason for alterations in preeclampsia? Placenta 2010,
31:910-918.
15. Fournier T, Handschuh K, Tsatsaris V, Guibourdenche J, Evain-Brion D: Role
of nuclear receptors and their ligands in human trophoblast invasion. J
Reprod Immunol 2008, 77:161-170.
16. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y,
Lim KH, Yuan HT, Libermann TA, et al: Soluble endoglin contributes to the
pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
17. Henry-Berger J, Mouzat K, Baron S, Bernabeu C, Marceau G, Saru JP, Sapin V,
Lobaccaro JM, Caira F: Endoglin (CD105) expression is regulated by the
liver X receptor alpha (NR1H3) in human trophoblast cell line JAR. Biol
Reprod 2008, 78:968-975.
18. Legry V, Cottel D, Ferrieres J, Chinetti G, Deroide T, Staels B, Amouyel P,
Meirhaeghe A: Association between liver X receptor alpha gene
polymorphisms and risk of metabolic syndrome in French populations.
Int J Obes (Lond) 2008, 32:421-428.
19. Robitaille J, Houde A, Lemieux S, Gaudet D, Perusse L, Vohl MC: The
lipoprotein/lipid profile is modulated by a gene-diet interaction effect
between polymorphisms in the liver X receptor-alpha and dietary
cholesterol intake in French-Canadians. Br J Nutr 2007, 97:11-18.
20. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, Jones CG,
Zaitlen NA, Varilo T, Kaakinen M, et al: Genome-wide association analysis
of metabolic traits in a birth cohort from a founder population. Nat
Genet 2009, 41:35-46.
21. Dahlman I, Nilsson M, Gu HF, Lecoeur C, Efendic S, Ostenson CG, Brismar K,
Gustafsson JA, Froguel P, Vaxillaire M, et al: Functional and genetic
analysis in type 2 diabetes of liver X receptor alleles–a cohort study.
BMC Med Genet 2009, 10:27.
22. Dahlman I, Nilsson M, Jiao H, Hoffstedt J, Lindgren CM, Humphreys K,
Kere J, Gustafsson JA, Arner P, Dahlman-Wright K: Liver X receptor gene
polymorphisms and adipose tissue expression levels in obesity.
Pharmacogenet Genomics 2006, 16:881-889.
23. Ketterer C, Mussig K, Machicao F, Stefan N, Fritsche A, Haring HU, Staiger H:
Genetic variation within the NR1H2 gene encoding liver X receptor beta
associates with insulin secretion in subjects at increased risk for type 2
diabetes. J Mol Med (Berl) 2011, 89:75-81.
24. Solaas K, Legry V, Retterstol K, Berg PR, Holven KB, Ferrieres J, Amouyel P,
Lien S, Romeo J, Valtuena J, et al: Suggestive evidence of associations
between liver X receptor beta polymorphisms with type 2 diabetes
mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA
(France) and HELENA (Europe). BMC Med Genet 2010, 11:144.
Mouzat et al. BMC Medical Genetics 2011, 12:145
http://www.biomedcentral.com/1471-2350/12/145
Page 8 of 9
25. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-
Neveu S, Balducchi JP, Daures JP, Perneger T, Quere I, Dauzat M, et al:
Factor V Leiden and prothrombin G20210A polymorphisms as risk
factors for miscarriage during a first intended pregnancy: the matched
case-control ‘NOHA first’ study. J Thromb Haemost 2005, 3:2178-2184.
26. Cochery-Nouvellon E, Nguyen P, Attaoua R, Cornillet-Lefebvre P, Mercier E,
Vitry F, Gris JC: Interleukin 10 gene promoter polymorphisms in women
with pregnancy loss: preferential association with embryonic wastage.
Biol Reprod 2009, 80:1115-1120.
27. Raynal C, Ciccolini J, Mercier C, Boyer JC, Polge A, Lallemant B, Mouzat K,
Lumbroso S, Brouillet JP, Evrard A: High-resolution melting analysis of
sequence variations in the cytidine deaminase gene (CDA) in patients
with cancer treated with gemcitabine. Ther Drug Monit 2010, 32:53-60.
28. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21:263-265.
29. Myers SA, Wang SC, Muscat GE: The chicken ovalbumin upstream
promoter-transcription factors modulate genes and pathways involved
in skeletal muscle cell metabolism. J Biol Chem 2006, 281:24149-24160.
30. Balding DJ: A tutorial on statistical methods for population association
studies. Nat Rev Genet 2006, 7:781-791.
31. O’Brien TE, Ray JG, Chan WS: Maternal body mass index and the risk of
preeclampsia: a systematic overview. Epidemiology 2003, 14:368-374.
32. Carty DM, Delles C, Dominiczak AF: Novel biomarkers for predicting
preeclampsia. Trends Cardiovasc Med 2008, 18:186-194.
33. Shah TJ, Walsh SW: Activation of NF-kappaB and expression of COX-2 in
association with neutrophil infiltration in systemic vascular tissue of
women with preeclampsia. Am J Obstet Gynecol 2007, 196:48 e41-48.
34. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP: Inflammatory
cytokines in the pathophysiology of hypertension during preeclampsia.
Curr Hypertens Rep 2007, 9:480-485.
35. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P: Reciprocal
regulation of inflammation and lipid metabolism by liver X receptors.
Nat Med 2003, 9:213-219.
36. Walczak R, Joseph SB, Laffitte BA, Castrillo A, Pei L, Tontonoz P:
Transcription of the vascular endothelial growth factor gene in
macrophages is regulated by liver X receptors. J Biol Chem 2004,
279:9905-9911.
37. Pavan L, Hermouet A, Tsatsaris V, Therond P, Sawamura T, Evain-Brion D,
Fournier T: Lipids from oxidized low-density lipoprotein modulate
human trophoblast invasion: involvement of nuclear liver X receptors.
Endocrinology 2004, 145:4583-4591.
38. Aye IL, Waddell BJ, Mark PJ, Keelan JA: Oxysterols inhibit differentiation
and fusion of term primary trophoblasts by activating liver X receptors.
Placenta 2011, 32:183-191.
39. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency
and power in genetic association studies. Nat Genet 2005, 37:1217-1223.
40. Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med
2006, 355:2615-2617.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/145/prepub
doi:10.1186/1471-2350-12-145
Cite this article as: Mouzat et al.: A common polymorphism in NR1H2
(LXRbeta) is associated with preeclampsia. BMC Medical Genetics 2011
12:145.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mouzat et al. BMC Medical Genetics 2011, 12:145
http://www.biomedcentral.com/1471-2350/12/145
Page 9 of 9
